UniQure

UniQure is a company listed under the stock ticker QURE (NL).

View the org chart displaying its 18 main executives

Most searched biographies at UniQure

• Matthew Kapusta, Chief Executive Officer and Executive Director
• Paula Soteropoulos, Member of the Supervisory Board (until Dec 19 ...
• David Meek, Chairman of the Board

Popular executive movements at UniQure

• Paula Soteropoulos, Member of the Supervisory Board, will leave the company on Dec. 19, 2024  (posted on April 15 2024).
• Ricardo Dolmetsch, President and Chief Scientific Officer, has left the company  (posted on October 11 2023).

Create your alert
to follow the executive moves at UniQure.

UniQure has 2,277 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Histogen has filed for bankruptcy protection  (posted on April 19 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on April 18 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by UniQure

Social media about UniQure

• UniQure on Wikipedia, Google News & Yahoo Finance
• UniQure on LinkedIn, Twitter & YouTube

Contact by email its executives including Matthew Kapusta

Call UniQure at +31 20...

View the org chart

Register to receive your alert

Report an error